BioSyent Inc. RX.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · biosyent.com
BioSyent Inc. is a Canadian specialty healthcare company that acquires, licenses, develops, and commercializes pharmaceutical and other healthcare products in Canada and internationally. The company's portfolio includes FeraMAX (iron deficiency anemia treatment), Tibella (hormone replacement therapy), RepaGyn, Cathejell, and Proktis-M, with a focus on innovative products sourced through international partnerships that offer therapeutic advantages and defensible intellectual property.
Key ratios
CashFromOperationsYoYGrowth TTM 0.78
CashFromOperationsYoYGrowth 2025 0.04
CashFromOperationsYoYGrowth 2024 0.71
CashFromOperationsYoYGrowth 2023 0.02
DilutedEPSYoYGrowth TTM 0.18
DilutedEPSYoYGrowth 2025 0.27
DilutedEPSYoYGrowth 2024 0.16
DilutedEPSYoYGrowth 2023 0.22
FreeCashFlowOnSale TTM 0.27
FreeCashFlowOnSale 2025 0.21
FreeCashFlowOnSale 2024 0.25
FreeCashFlowOnSale 2023 0.16
NetIncomeMargin TTM 0.2
NetIncomeMargin 2025 0.21
NetIncomeMargin 2024 0.21
NetIncomeMargin 2023 0.2
ReturnOnAssets TTM 0.13
ReturnOnAssets 2025 0.15
ReturnOnAssets 2024 0.14
ReturnOnAssets 2023 0.11
ReturnOnEquity TTM 0.22
ReturnOnEquity 2025 0.24
ReturnOnEquity 2024 0.21
ReturnOnEquity 2023 0.19
TotalRevenueYoYGrowth TTM 0.2
TotalRevenueYoYGrowth 2025 0.23
TotalRevenueYoYGrowth 2024 0.11
TotalRevenueYoYGrowth 2023 0.13
Recent news
BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)
2026-05-19 · GlobeNewswire
BioSyent Releases Financial Results for First Quarter 2026
2026-05-14 · GlobeNewswire
BioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026
2026-05-07 · GlobeNewswire
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
2026-03-19 · GlobeNewswire
BioSyent Announces Closing of the Acquisition of Oral Science Inc.
2026-03-02 · GlobeNewswire
BioSyent to Acquire Oral Science Inc.
2026-02-09 · GlobeNewswire